Phase 3 N=11 Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan
Neuroendocrine Tumors
Primary: Sensitivity to Correctly Diagnose NET — 75; 75; 100; 75 percent of NET correctly diagnosed
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=59 Patient- and Caregiver-reported Symptoms and Outcomes With Levodopa/Carbidopa Intestinal Gel for the Treatment of Advanced Parkinson's Disease
Parkinson's Disease
Primary: Change From Baseline in Parkinson's Disease Questionnaire-39 Item (PDQ-39) Global Score at Month 6 — -12.81 units on a scale — p=< 0.0001
Phase 3 N=1,203 Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy
Subclinical Hypothyroidism · Hypothyroxinemia · Pregnancy
Primary: Intellectual Function of Children at 5 Years of Age in Women Diagnosed With a) Subclinical Hypothyroidism or b) Hypothyroxinemia During the First Half of Pregnancy, or…
Phase 3 N=713 A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) — 16.8; 5.6 Months…
Phase 2 N=26 Verapamil for Beta Cell Survival Therapy in Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: Functional Beta Cell Mass — 0.74; 0.46 nmol/L
Phase 2 N=30 Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2
Molluscum Contagiosum
Primary: Number of Participants With Total Lesion Clearance — 11 Participants
N/A N=2,320 Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States
Hypothyroidism
Primary: Incidence Rate of Hypothyroidism Detected in Routine Clinical Practice — 15.9 events per 1,000 person years
Phase 2 N=170 A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia
Schizophrenia
Primary: Visual Memory — 37.1; 33.9; 39.6; 34.2 visual memory scores
N/A N=35 30-Minute Light Exposure for the Treatment of Seasonal Affective Disorder
Seasonal Affective Disorder
Primary: SIGH-ADS Score — 29.4; 25.8; 5.6; 4.5 units on a scale — p=0.74
Phase 2 N=122 Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients
Influenza · Multiple Myeloma · Waldenstrom's Macroglobulinemia
Primary: Number of Participants With Treatment Failure by Primary Endpoint — 26; 13 Participants
N/A N=44 Cranial Laser Reflex Technique for Hamstring Function
Hamstring Injury · Muscle Tone Increased · Muscle Pain
Primary: 90-90 Knee Extension Angle Test — 167.3; 166.4; 168.5; 168.8 degrees
N/A N=36 Comparison of Two Silicone Hydrogel Toric Contact Lenses
Astigmatism
Primary: Percentage of Lenses With Axis Orientation Within ±30 Degrees From the 90 Degree Axis (Ideal Location) — 94.4; 95.8 percentage of lenses
Phase 2 N=22 Atomoxetine and Oxybutynin in Obstructive Sleep Apnea
Obstructive Sleep Apnea (OSA)
Primary: Apnea Hypopnea Index (AHI, Events/Hour of Sleep) — 28.5; 7.5 events/hours of sleep — p=<0.001
Phase 3 N=66 A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura
Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP
Primary: Number of Participants With Adverse Events — 64; 19; 2; 1 Participants
Phase 4 N=42 Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients
Type 2 Diabetes
Primary: CD34+ Endothelial Progenitor Cells Number — 2.0; 2.8 % of Mononuclear Cells